Skye Bioscience, Inc. Capital Expenditures Incurred but Not yet Paid
Skye Bioscience, Inc. (SKYE) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-22.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-03-22
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was $0.00.
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$849.03K.
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $190.53K, a 381.04% increase year-over-year.
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Skye Bioscience, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $102.86K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 9 month as first filed | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $0.00 derived: sum of 2 quarters · filed 2024-03-22 | $0.00 10-K · filed 2024-03-22 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | ||||
| 2022-12-31 | -$849.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$658.51K derived: sum of 2 quarters · filed 2024-03-22 | $102.86K 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $190.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $951.89K 10-Q · filed 2023-11-14 | $10.46K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $761.36K 10-Q · filed 2023-08-07 | ||||
| 2021-09-30 | $39.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $39.61K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |